Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels

Diabetes, Obesity & Metabolism
H BlauwPCDIAB consortium

Abstract

To evaluate the pharmacokinetics and pharmacodynamics of different doses of glucagon administered subcutaneously (s.c.) at different blood glucose levels. This study was an open-label, randomized, three-period, cross-over experiment in 6 patients with type 1 diabetes. During each of the three periods, different blood glucose levels were established in four consecutive steps (8, 6, 4 and 2.8 mmol/l) and glucagon was given at each blood glucose level in doses from 0.11 to 0.44 mg and 0.33, 0.66 and 1 mg at the lowest glucose concentration. Maximum glucagon concentration and area under the curve increased with increasing glucagon dose. Maximum glucagon concentration was reached after 10-20 min. Glucagon raised blood glucose in a dose-dependent manner at different baseline blood glucose levels. The median glucose excursion ranged from 2.6 to 6.2 mmol/l. Time to maximum glucose concentration was dose-dependent for the glucagon doses at 2.8 mmol/l, with median values from 40 to 80 min. Glucagon administered s.c. produces a stable pharmacokinetic and pharmacodynamic response at lower doses than the usual rescue dose and across a range of hypo- to hyperglycaemic blood glucose levels. This supports the use of small glucagon doses in the...Continue Reading

References

Oct 9, 1999·Journal of Pharmaceutical Sciences·M Yazdanian
Apr 24, 2001·Diabetes Care·M W Haymond, B Schreiner
Mar 3, 2006·Journal of Paediatrics and Child Health·Mary HartleyAndrew M Cotterill
Apr 12, 2007·Diabetes Technology & Therapeutics·Firas H El-KhatibEdward R Damiano
Dec 7, 2010·Journal of Diabetes Science and Technology·Steven J RussellEdward R Damiano
Dec 7, 2010·Journal of Diabetes Science and Technology·Jessica R CastleW Kenneth Ward
Aug 28, 2012·Diabetes Care·Steven J RussellEdward R Damiano
Jan 30, 2013·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Ahmad HaidarRémi Rabasa-Lhoret
Dec 20, 2013·Journal of Diabetes Science and Technology·Ahmad HaidarRémi Rabasa-Lhoret
Feb 4, 2014·The Journal of Clinical Endocrinology and Metabolism·Firas H El-KhatibEdward R Damiano

❮ Previous
Next ❯

Citations

Mar 22, 2016·Diabetes, Obesity & Metabolism·H BlauwUNKNOWN , on behalf of the PCDIAB consortium
Oct 19, 2016·Biomarkers in Medicine·Nicolai J Wewer AlbrechtsenJens J Holst
Sep 16, 2016·Diabetes, Obesity & Metabolism·Nadine TalebRémi Rabasa-Lhoret
Jan 18, 2018·Diabetic Medicine : a Journal of the British Diabetic Association·T M Peters, A Haidar
Nov 30, 2018·BMJ Open Diabetes Research & Care·Ilze Dirnena-FusiniSverre Christian Christiansen
Jun 28, 2017·Journal of Diabetes Science and Technology·Sabrina Lyngbye WendtJohn Bagterp Jørgensen
Oct 17, 2018·Pharmaceutical Research·Jens Kvist MadsenDaniel E Otzen
Sep 29, 2019·Diabetes Technology & Therapeutics·Christian LaugesenAjenthen G Ranjan
Apr 9, 2020·Expert Opinion on Pharmacotherapy·Shujuan LiLi Wang
Jan 26, 2020·Endocrinology and Metabolism Clinics of North America·Leah M WilsonJessica R Castle
Oct 23, 2020·Diabetes/metabolism Research and Reviews·Ajenthen G RanjanKirsten Nørgaard
Jun 9, 2021·European Journal of Drug Metabolism and Pharmacokinetics·Ingrid Anna TeigenSverre Christian Christiansen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.